Brought to you by 
Merck Serono spins out GI-focused Calypso Biotech; seeds with €2.5mm
27 Mar 2013
Executive Summary
Merck Serono SA and its Entrepreneur Partnership Program (EPP) have spun out their sixth new company, Calypso Biotech, which will focus on Merck’s preclinical therapeutic antibodies for inflammatory bowel diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck Serono spins out GI-focused Calypso Biotech; seeds with €2.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice